A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).
彭星辰 四川大学华西医院 Initial Results of the Multicenter Phase 2 Trial of a Novel Hypofractionated Low-dose Radiotherapy for Indolent non-Hodgkin Lymphoma 新型大分割低剂量放疗治疗惰性非霍奇金淋巴瘤的多中心II期试验的初步结果汇报讲者:王心悦 天津市肿瘤医院 ...
Most prostate cancers are “indolent,” meaning they’ll never metastasize during a patient’s lifetime and treatment could do more harm than good. At the same time, they’re the second highest cause of ...